$ACRV Balance Sheet | Understand Stock

$ACRV

$1.72 -$0.01 (0.58%) Close

$ACRV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Long-term investments
Restricted cash
Deferred offering costs
Other assets
Total assets
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities, current
Total current liabilities
Operating lease liabilities, non-current
Total liabilities
Series convertible preferred stock
Series A-1 Convertible Preferred Stock
Series B Convertible Preferred Stock
Total series convertible preferred stock
Stockholders’ deficit:
Common stock, $0.001 par value; 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 42,847,215 and 31,648,856 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments